deltatrials
Unknown PHASE4 INTERVENTIONAL 2-arm NCT04655170

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD

Randomized, Parallel-group Trial to Evaluate Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD

Sponsor: Mylan Pharmaceuticals Inc

Conditions COPD Exacerbation
Interventions Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic) Revefenacin (YUPELRI) & Formoterol (Perforomist)
Updated 7 times since 2021 Last updated: Nov 13, 2022 Started: Dec 9, 2020 Primary completion: Jan 30, 2023 Completion: Mar 30, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on COPD Exacerbation, this trial is ongoing. The trial is conducted by Mylan Pharmaceuticals Inc and has accumulated 7 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Oct 2022 · 17 months · monthly snapshotRecruiting~Oct 2022 – ~Dec 2022 · 2 months · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – present · 19 months · monthly snapshotUnknown

Change History

7 versions recorded

  1. Dec 2024 — Present [monthly]

    Unknown PHASE4

    Status: Recruiting → Unknown

  2. Sep 2024 — Dec 2024 [monthly]

    Recruiting PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE4

  4. Dec 2022 — Jul 2024 [monthly]

    Recruiting PHASE4

  5. Oct 2022 — Dec 2022 [monthly]

    Recruiting PHASE4

▶ Show 2 earlier versions

  1. May 2021 — Oct 2022 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  2. Jan 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Dec 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mylan Pharmaceuticals Inc
  • University of Tennessee Graduate School of Medicine
Data source: University of Tennessee Graduate School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations